Liquid Biopsy for Early Detection of Pancreatic Cancer
Most pancreatic cancer patients present with advanced metastatic disease, resulting in extremely poor 5-year survival, mainly because there is no reliable modality for early detection of this disease. Therefore, there is a need for less-invasive diagnostic tools for detecting pancreatic cancer at an early stage, when curative surgery may be feasible. “Liquid biopsy” addresses this unmet clinical need based on the concept that simple peripheral blood sampling and detection of circulating tumor DNA (ctDNA) could provide diagnostic information. Recent technological advances have enabled detection of genomic alterations in ctDNA in blood samples from cancer patients. In this chapter, we provide an overview of the current status of blood-based tests for diagnosis of pancreatic cancer, and we also discuss challenges that remain to be addressed in developing practical ctDNA-based liquid biopsy for early diagnosis of pancreatic cancer.
KeywordsCirculating tumor DNA Liquid biopsy Biomarker
- 25.Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther. 2008;7:353–60.CrossRefPubMedGoogle Scholar
- 26.Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, et al. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol. 2015;13:963–9.CrossRefPubMedGoogle Scholar